Login

Switch On Your HIV Smarts.

Surprising price break for newly-approved hepatitis C drug

Surprising price break for newly-approved hepatitis C drug

, by Liz Highleyman

Two new hepatitis C cure drugs, Mavyret and Vosevi, have been approved by the FDA—offering a shorter course of treatment, for a lower cost. Read More

Long-acting antiretrovirals for HIV treatment and PrEP

Long-acting antiretrovirals for HIV treatment and PrEP

, by Liz Highleyman

At the recent IAS 2017 conference, we got good news about the safety and efficacy of a long-acting antiretroviral injection and a drug in a new class of medications. Read More

Do you know U=U?

Do you know U=U?

, by Emily Newman

Advocates for “Undetectable=Untransmittable” (U=U) were out, proud and visible this year at the International AIDS Conference, spreading the message that people living with HIV with undetectable viral loads do not transmit HIV to partners. Read More

What’s new with PrEP? Research & innovation at IAS 2017

What’s new with PrEP? Research & innovation at IAS 2017

, by Emily Newman

Read more about studies of on-demand dosing, a long-acting injectable, and PrEP and STIs. Read More

For people with HIV, higher HDL cholesterol linked to improved cognition

For people with HIV, higher HDL cholesterol linked to improved cognition

, by Emily Newman

New research from #IAS2017 shows that the risk of cognitive impairment is reduced by 11% with every 10 mg/dL increase in HDL cholesterol. Read More